-
-
Overview
-
Rifampicin (rifampin) is a semisynthetic antimicrobial compound derived from rifamycin SV and originally developed by the Lepetit group in 1965. Rifampicin shows activity against gram-positive bacteria, particularly mycobacteria like tuberculosis, some gram-negative anaerobic bacteria, protozoa, fungi, and poxviruses.
Rifampicin inhibits the assembly of DNA and protein into mature virus particles. It inhibits initiation of RNA synthesis by binding to β-subunit of RNA polymerase, which results in cell death.
Rifampicin has been shown to inhibit α-synuclein fibrillation and disaggregate fibrils in a concentration-dependent manner. Rifampicin can activate pregnane X receptor (PXR), which affects cytochrome P450, and the activity of glucuronosyltransferases and P-glycoprotein. Rifampicin has been shown to enhance CYP2C-mediated metabolism, affect compounds that are transported by P-glycoprotein and metabolized by CYP3A4.
Rifampicin is an immunosuppressive agent.
For a safer, and easier to use Rifampicin, try our ready-made Rifampicin Solution (10 mg/mL in water).Please contact us at for specific academic pricing.
Background
Rifampicin targets prokaryotic DNA dependent RNA polymerases which prevent subsequent RNA transcription and protein translation.
-
- Properties
- Applications
-
Overview